alanine has been researched along with Peptic Ulcer in 12 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Peptic Ulcer: Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study is to elucidate the effects and the mechanism of rebamipide, omeprazole, and their combination treatment on quality of peptic ulcer healing (QOUH)." | 3.75 | Effect of rebamipide on quality of peptic ulcer healing in rat. ( Haixia, C; Jie, L; Qi, Z; Xiaoying, Z, 2009) |
| " The long-term use of proton pump inhibitors (PPIs) is associated with adverse events." | 2.90 | Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial. ( Chaitongrat, S; Lertsuwunseri, V; Mahachai, V; Pittayanon, R; Piyachaturawat, P; Prueksapanich, P; Rerknimitr, R; Srimahachota, S, 2019) |
| " Adverse events were recorded by patients in specially developed diaries." | 2.87 | Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. ( Andreev, DN; Dicheva, DT; Maev, IV; Partzvania-Vinogradova, EV; Samsonov, AA, 2018) |
| " The grade of gastric mucosal injuries was evaluated by esophagogastroduodenoscopy before and after dosing (on day 0 and day 14), and the grade of gastric mucosal injury was assessed according to the modified Lanza score." | 2.79 | A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. ( Fukui, H; Hida, N; Hori, K; Miwa, H; Nakamura, S; Ogawa, T; Ohda, Y; Okugawa, T; Oshima, T; Tomita, T; Tozawa, K; Watari, J, 2014) |
| "We examined 90 patients with early gastric cancer who had undergone ESD." | 2.78 | Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. ( Asakuma, Y; Kashida, H; Kawasaki, M; Kudo, M; Matsui, S; Sakurai, T; Takayama, M, 2013) |
| " Sixty patients received 40 mg of omeprazole twice a day, 1500 mg of amoxicillin three times a day, and 300 mg of rebamipide three times a day (group OAR); the other 60 patients received the same dosage of omeprazole and amoxicillin but no rebamipide for two weeks (group OA)." | 2.69 | Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer. ( Ando, K; Arakawa, T; Harihara, S; Higuchi, K; Ito, H; Kobayashi, K; Kuroki, T; Nebiki, H; Uchida, T, 1998) |
| "This study aimed to detect safety signals of rebamipide and search for adverse events (AEs) of rebamipide that are more common than those of other drugs for peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD) in the elderly population." | 1.72 | Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease. ( Jang, E; Jeong, JE; Kim, MG; Lee, JY; Park, M, 2022) |
| "Diclofenac can cause gastric mucosal lesions, including ulcers, more easily than other NSAIDs." | 1.34 | Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis. ( Fukui, H; Takakura, Y; Yajima, H; Yamao, J, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jang, E | 1 |
| Park, M | 1 |
| Jeong, JE | 1 |
| Lee, JY | 1 |
| Kim, MG | 1 |
| Andreev, DN | 1 |
| Maev, IV | 1 |
| Dicheva, DT | 1 |
| Samsonov, AA | 1 |
| Partzvania-Vinogradova, EV | 1 |
| Pittayanon, R | 1 |
| Piyachaturawat, P | 1 |
| Rerknimitr, R | 1 |
| Prueksapanich, P | 1 |
| Chaitongrat, S | 1 |
| Lertsuwunseri, V | 1 |
| Srimahachota, S | 1 |
| Mahachai, V | 1 |
| Takayama, M | 1 |
| Matsui, S | 1 |
| Kawasaki, M | 1 |
| Asakuma, Y | 1 |
| Sakurai, T | 1 |
| Kashida, H | 1 |
| Kudo, M | 1 |
| Tozawa, K | 1 |
| Oshima, T | 1 |
| Okugawa, T | 1 |
| Ogawa, T | 1 |
| Ohda, Y | 1 |
| Tomita, T | 1 |
| Hida, N | 1 |
| Fukui, H | 2 |
| Hori, K | 1 |
| Watari, J | 1 |
| Nakamura, S | 1 |
| Miwa, H | 1 |
| Qi, Z | 1 |
| Jie, L | 1 |
| Haixia, C | 1 |
| Xiaoying, Z | 1 |
| Arakawa, T | 2 |
| Higuchi, K | 2 |
| Fujiwara, Y | 1 |
| Watanabe, T | 1 |
| Tominaga, K | 1 |
| Sasaki, E | 1 |
| Oshitani, N | 1 |
| Yoshikawa, T | 1 |
| Tarnawski, AS | 1 |
| Yajima, H | 1 |
| Yamao, J | 1 |
| Takakura, Y | 1 |
| Han, BG | 1 |
| Kim, HS | 1 |
| Rhee, KH | 1 |
| Han, HS | 1 |
| Chung, MH | 1 |
| Hahm, KB | 1 |
| Lee, KJ | 1 |
| Kim, YS | 1 |
| Kim, JH | 1 |
| Cho, SW | 1 |
| Yim, H | 1 |
| Joo, HJ | 1 |
| Nebiki, H | 1 |
| Ando, K | 1 |
| Uchida, T | 1 |
| Ito, H | 1 |
| Harihara, S | 1 |
| Kuroki, T | 1 |
| Kobayashi, K | 1 |
| Shimoyama, T | 1 |
| Fukuda, S | 1 |
| Liu, Q | 1 |
| Sugawara, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cytoprotective Agent for Peptic Ulcer Prevention in Patients Taking Dual Antiplatelet Agents: A Randomized Double-blind Placebo Control Trial Study[NCT02166008] | Phase 2/Phase 3 | 142 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for alanine and Peptic Ulcer
| Article | Year |
|---|---|
15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications.
Topics: Alanine; Anti-Ulcer Agents; Antioxidants; Chemoprevention; Growth Substances; Humans; Peptic Ulcer; | 2005 |
[Rebamipide].
Topics: Alanine; Anti-Ulcer Agents; Antioxidants; Cytokines; Drug Therapy, Combination; Gastric Mucosa; Heli | 2002 |
6 trials available for alanine and Peptic Ulcer
| Article | Year |
|---|---|
Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study.
Topics: Adult; Alanine; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administ | 2018 |
Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial.
Topics: Aged; Alanine; Anti-Ulcer Agents; Aspirin; Cilostazol; Clopidogrel; Cytoprotection; Double-Blind Met | 2019 |
Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers.
Topics: Adenocarcinoma; Aged; Alanine; Anti-Ulcer Agents; Dissection; Female; Gastroscopy; Humans; Iatrogeni | 2013 |
A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel.
Topics: Adult; Alanine; Anti-Ulcer Agents; Aspirin; Clopidogrel; Double-Blind Method; Gastric Mucosa; Gastro | 2014 |
Augmented eradication rates of Helicobacter pylori by new combination therapy with lansoprazole, amoxicillin, and rebamipide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alanine; Amoxicillin; Anti-Infective Agents; A | 1998 |
Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer.
Topics: Adult; Aged; Alanine; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Fem | 1998 |
4 other studies available for alanine and Peptic Ulcer
| Article | Year |
|---|---|
Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Alanine; Gastroesophageal Reflux; Humans; Peptic Ulce | 2022 |
Effect of rebamipide on quality of peptic ulcer healing in rat.
Topics: Alanine; Animals; Anti-Ulcer Agents; Dinoprostone; Drug Therapy, Combination; Gastric Mucosa; Interl | 2009 |
Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis.
Topics: Adult; Aged; Alanine; Anti-Ulcer Agents; Bone Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; End | 2007 |
Effects of rebamipide on gastric cell damage by Helicobacter pylori-stimulated human neutrophils.
Topics: Alanine; Animals; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Helicobacter pylori; Humans; | 1995 |